Drugs Made In America Acquisition Corp.
DMAA
$10.54
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.09M | 263.70K | 131.90K | 330.90K | 279.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.09M | 263.70K | 131.90K | 330.90K | 279.90K |
| Operating Income | -2.09M | -263.70K | -131.90K | -330.90K | -279.90K |
| Income Before Tax | 213.00K | 2.18M | 2.29M | 1.25M | -279.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 213.00K | 2.18M | 2.29M | 1.25M | -279.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 213.00K | 2.18M | 2.29M | 1.25M | -279.90K |
| EBIT | -2.09M | -263.70K | -131.90K | -330.90K | -279.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.01 | 0.07 | 0.07 | 0.05 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.04 | 0.04 | 0.03 | -0.02 |
| EPS Diluted | 0.01 | 0.07 | 0.07 | 0.05 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.04 | 0.04 | 0.03 | -0.02 |
| Average Basic Shares Outstanding | 34.19M | 33.52M | 33.52M | 24.79M | 8.57M |
| Average Diluted Shares Outstanding | 34.19M | 33.52M | 33.52M | 25.51M | 8.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |